# Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer

> **NCT00320710** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 416 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Zoledronic acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00320710
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2014-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00320710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00320710, "Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00320710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*